ArticleNature2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Open access · hybridAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 326 papers.
0numbers the graph read from it
0cells of the map it votes in
326citing papers in PubMed
126.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
326 citing papers in PubMed, 435 citations in OpenAlex.
- Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study.The Lancet. Haematology · 2026Trial
- Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.British journal of haematology · 2026Trial
- Trial
- Trial
- Trial
- Lineage switch in leukemia and lymphoma: case reports and molecular and cellular mechanisms.Blood neoplasia · 2026Review
- Current and future therapies for acute myeloblastic leukemia.Journal of hematology & oncology · 2026Review
- Article
- MEN1/menin deficiency suppresses hepatocellular carcinogenesis via disrupting mitophagy-mediated mitochondrial homeostasis.Autophagy · 2026Article
- First-year results of the International Leukemia/ Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.Haematologica · 2026Article
- Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.British journal of cancer · 2026Review
- Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.Blood · 2026Article
- Targeting Exportin-1 in Cancer: From Nuclear Export to Oncogenic Transcriptional Hubs.JMA journal · 2026Review
- Systemic Metabolic Changes in Plasma of Patients with Myelodysplastic Neoplasms and Chronic Myelomonocytic Leukemia.Metabolites · 2026Article
- NPM1-rearranged AML: clinical features, molecular pathogenesis, and therapeutic perspectives.International journal of hematology · 2026Review
- Mechanisms of post-transplant AML relapse and therapeutic implications.Bone marrow transplantation · 2026Article
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.Leukemia · 2026Article
- Genomic Characterization of Epigenetic Regulator Gene Alterations in Juvenile Myelomonocytic Leukemia Through Whole-Exome Sequencing.Epigenomes · 2026Article
- Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms.Cancer cell · 2026Article
266 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
24 authors at 11 institutions in 2 countries.
Ghayas C IssaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. gcissa@mdanderson.org.ORCID http://orcid.org/0000-0002-4339-8683
Ibrahim AldossCity of Hope, Duarte, CA, USA.
John DiPersioWashington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-0429-3133
Branko CuglievanDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Richard StoneDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7526-2633
Martha ArellanoWinship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Michael J ThirmanUniversity of Chicago, Chicago, IL, USA.
Manish R PatelFlorida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA.
David S DickensUniversity of Iowa, Iowa City, IA, USA.
Shalini ShenoyWashington University School of Medicine in St. Louis, St. Louis, MO, USA.
Neerav ShuklaMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1908-3307
Scott A ArmstrongDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9099-4728
Florian PernerDana-Farber Cancer Institute, Boston, MA, USA.
Jennifer A PerryDana-Farber Cancer Institute, Boston, MA, USA.
Galit RosenSyndax Pharmaceuticals, Waltham, MA, USA.
Rebecca G BagleySyndax Pharmaceuticals, Waltham, MA, USA.
Michael L MeyersSyndax Pharmaceuticals, Waltham, MA, USA.
Peter OrdentlichSyndax Pharmaceuticals, Waltham, MA, USA.
Yu GuSyndax Pharmaceuticals, Waltham, MA, USA.
Vinit KumarSyndax Pharmaceuticals, Waltham, MA, USA.
Steven SmithSyndax Pharmaceuticals, Waltham, MA, USA.
Gerard M McGeehanSyndax Pharmaceuticals, Waltham, MA, USA.
Eytan M SteinMemorial Sloan Kettering Cancer Center, New York, NY, USA. steine@mskcc.org.
Synta Pharmaceuticals (United States) · USDana-Farber Cancer Institute · USThe University of Texas MD Anderson Cancer Center · USMemorial Sloan Kettering Cancer Center · USWashington University in St. Louis · USCity of Hope · USEmory University · USSarah Cannon · USUniversitätsmedizin Greifswald · DEUniversity of Illinois Chicago · USUniversity of Iowa · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MViral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0MPaul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI STEGMAIER, KIMBERLY · 2017 to 2021
$10.6MDefining epigenetic mechanisms in NPM1c mutant leukemiaR01CA259273 · NCI · DANA-FARBER CANCER INST · PI ARMSTRONG, SCOTT A · 2021 to 2025
$2.0MNCI NIH HHS K12 CA088084NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA259273
Abstract
Targeting critical epigenetic regulators reverses aberrant transcription in cancer, thereby restoring normal tissue function
Indexed as
Antineoplastic AgentsHistone-Lysine N-MethyltransferaseLeukemia, Myeloid, AcuteNucleophosminProto-Oncogene ProteinsBenzamidesHumansMyeloid-Lymphoid Leukemia ProteinNeoplasm, ResidualPrognosisProtein BindingRemission InductionSpiro CompoundsAntineoplastic AgentsBenzamidesHistone-Lysine N-MethyltransferaseKMT2A protein, humanMEN1 protein, humanMyeloid-Lymphoid Leukemia ProteinNPM1 protein, humanNucleophosminProto-Oncogene ProteinsrevumenibSpiro Compounds
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.